Lipid abnormalities in insulin resistant states

Reviews in Cardiovascular Medicine

Volumn 4, Issue 4, 2003, Pages 228-236

  Watson, Karol E ^a,b   Horowitz, Barbara N ^a   Matson, Gary ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Inst for Insulin Resistance Studies   (United States)

Author keywords

Insulin resistance; Lipoproteins; Metabolic syndrome

Indexed keywords

FENOFIBRATE; GEMFIBROZIL; GLIBENCLAMIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; METFORMIN; NICOTINIC ACID; PIOGLITAZONE; ROSIGLITAZONE; VERY LOW DENSITY LIPOPROTEIN;

ATHEROGENESIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; CORONARY RISK; DISEASE EXACERBATION; DRUG MECHANISM; DYSLIPIDEMIA; EARLY DIAGNOSIS; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW;

ANTILIPEMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COMORBIDITY; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERLIPIDEMIAS; INSULIN RESISTANCE; MALE; PROGNOSIS; RISK ASSESSMENT; SEX DISTRIBUTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0346777296     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Miegs JB. Epidemiology of the insulin resistance syndrome. Curr Diab Rep. 2003;3:73-79.
2. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol (Adult Treatment Panel III). JAMA. 2001;28:2486-2497.
3. Consensus Development Conference on Insulin Resistance. November 5-6, 1997. American Diabetes Association. Diabetes Care. 1998;21:310-314.
4. Eschwege E, Richard JL, Thibult N, et al. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. The Paris Prospective Study, ten years later. Horm Metab Res. 1985;15:41-46.
5. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-689.
6. Garg A. Insulin resistance in the pathogenesis of dyslipidemia. Diabetes Care. 1996;19:387-389.
7. Karhapaa P, Malkki M, Laakso M. Isolated low HDL cholesterol. An insulin-resistant state. Diabetes. 1994;43:411-417.
8. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev. 2002;23:201-229.
9. Olefsky JM, Farquhar JW, Reaven GM. Reappraisal of the role of insulin in hypertriglyceridemia. Am J Med. 1974;57:551-560.
10. Sparks JE, Sparks CE. Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion. Biochem Biophys Acta. 1994;1215:9-32.
11. Lewis GF, Uffelman KD, Szeto LW, Steiner G. Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apo B production in normal weight and obese individuals. Diabetes. 1993;42:833-842.
12. Sparks JD, Sparks CE. Obese Zucker (fa/fa) rats are resistant to insulin's inhibitory effect on hepatic apo B secretion. Biochem Biophys Res Commun. 1994;205:417-422.
13. Bourgeois CA, Wiggins D, Helms R, Gibbons GF. VLDL Output by hepatocytes from obese Zucker rats is resistant to the inhibitory effect of insulin. Am J Physiol. 1995;269:E208-E215.
14. Reaven GM. Insulin resistance and its consequences: non-insulin-dependent diabetes mellitus and coronary heart disease. In: LeRoith D, Taylor SI, Olefsky JM, eds. Diabetes Mellitus: A Fundamental and Clinical Text. Philadelphia: Lippincott-Raven; 1996:509-519.
15. Reaven GM, Chen YD, Jeppesen J, et al. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest. 1993;92:141-146.
16. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic market for coronary heart disease risk. Circulation. 1990;82:495-506.
17. Waring E, Pugh KB, Huang P, et al. Effects of insulin resistance and type 2 diabetes on the nuclear magnetic resonance lipoprotein subclass profile [abstract]. Diabetes. 2001;50(suppl 2):1-106,A1-649.
18. Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol. 1999;83:25F-29F.
19. Knowler WC, Narayan KM, Hanson RL, et al. Preventing non-insulin-dependent diabetes. Diabetes. 1995;44:483-488.
20. Eliasson B, Smith U. Insulin resistance. In: Reaven GM, Laws A, eds. Insulin Resistance: The Metabolic Syndrome X. Totowa, NJ: Humana Press; 1999:121-136.
21. Avandia® (rosiglitazone) [package insert]. Study 020. Research Triangle Park, NC: GlaxoSmithKline; 2003.
22. Parulkar AA, Pendergrass ML, Granda-Ayala R, et al. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med. 2001;134:61-71.
23. Pentikainen PJ, Voutilainen E, Aro A, et al. Cholesterol lowering effect of metformin in combined hyperlipidemia: placebo controlled double blind trial. Ann Med. 1990;22:307-312.
24. Chu NV, Kong AP, Kim DD, et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care. 2002;25:542-549.
25. Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med. 1999;159:2661-2667.
26. Chesney CM, Elam MB, Herd JA, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial. JAMA. 2000;284:1263-1270.
27. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001;357:905-910.
28. Lahdenpera S, Tilly-Kiesi M, Vuorinen-Markkola H, et al. Effects of gemfibrozil on low-density lipoprotein particle size, density distribution, and composition in patients with type II diabetes. Diabetes Care. 1993;16:584-592.
29. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
30. Berge KG, Canner PL. Coronary drug project: experience with niacin. Eur J Clin Pharmacol. 1991;40 (Suppl 1):S49-S51.
31. Rubins HB, Davenport J, Babikian V, et al. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol. The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation. 2001;103:2828-2833.
32. Taskinen MR. Controlling lipid levels in diabetes. Acta Diabetol. 2002;39(suppl 2):S29-S34.